Cargando…

First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB

The first successful use of bedaquiline for 18 months for XDR-TB as part of an optimised background regimen http://ow.ly/XE34x

Detalles Bibliográficos
Autores principales:	Lewis, Joseph M., Hine, Paul, Walker, Jenny, Khoo, Saye H., Taegtmeyer, Miriam, Squire, S. Bertel, Sloan, Derek J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2016
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394548/ https://www.ncbi.nlm.nih.gov/pubmed/26917618 http://dx.doi.org/10.1183/13993003.01980-2015

Ejemplares similares

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient
por: Ghodousi, Arash, et al.
Publicado: (2022)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Implementation of digital technology solutions for a lung health trial in rural Malawi
por: Chisunkha, Blessings, et al.
Publicado: (2016)

The (in)significance of TB and COVID-19 co-infection
por: Khurana, Alkesh Kumar, et al.
Publicado: (2020)

QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection
por: Saluzzo, Francesca, et al.
Publicado: (2022)

Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV
por: Kerkhoff, Andrew D., et al.
Publicado: (2020)

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
por: Masini, Tiziana, et al.
Publicado: (2022)

Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community
por: Mori, Toru, et al.
Publicado: (2015)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
por: Codecasa, Luigi R., et al.
Publicado: (2017)

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
por: Rosu, Laura, et al.
Publicado: (2020)

Collapse induration of alveoli is an ultrastructural finding in a COVID-19 patient
por: Ochs, Matthias, et al.
Publicado: (2021)

Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2022)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study
por: Shi, Li, et al.
Publicado: (2021)

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2019)

A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany
por: Bahrs, Christina, et al.
Publicado: (2022)

Resilience of the respiratory microbiome in controlled adult RSV challenge study
por: Cuthbertson, Leah, et al.
Publicado: (2022)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

The burden of progressive fibrotic interstitial lung disease across the UK
por: Simpson, Thomas, et al.
Publicado: (2021)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre Bedaquiline (BDQ) era
por: Utpat, Ketaki V., et al.
Publicado: (2023)

Job strain and COPD exacerbations: an individual-participant meta-analysis
por: Heikkilä, Katriina, et al.
Publicado: (2014)

Does a single Pseudomonas aeruginosa isolation predict COPD mortality?
por: Boutou, Afroditi K., et al.
Publicado: (2014)

Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax
por: Nikolić, Marko Z., et al.
Publicado: (2015)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

Bile acid aspiration in people with cystic fibrosis before and after lung transplantation
por: Brodlie, Malcolm, et al.
Publicado: (2015)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

Breathlessness, physical activity and sustainability of healthcare
por: Aitsi-Selmi, Amina, et al.
Publicado: (2015)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
por: Sotgiu, Giovanni, et al.
Publicado: (2015)

Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population
por: Taylor-Robinson, David C., et al.
Publicado: (2014)

Respiratory decline is integral to disease progression in Huntington's disease
por: Jones, Una, et al.
Publicado: (2016)

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region
por: Blok, Nick, et al.
Publicado: (2016)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

Tuberculosis prevention must integrate technological and basic care innovation
por: Mason, Paul H., et al.
Publicado: (2016)

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
por: Akkerman, Onno W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fu71dp6f2gtj3r8a7kr34028p0